Novel anti-hepatitis B virus-active catechin and epicatechin from .

Bioactive natural or phytoproducts have emerged as a potential source of antiviral agents. Of the spp., and have been reported for their antiviral activities against hepatitis B virus (HBV), while the anti-HBV efficacy of has remained elusive. In the present study, the anti-HBV activities of -derived novel catechin [3,5,13,14-flavantetrol-catechin or rhuspartin (RPT)] and epicatechin-3--rhamnoside (ECR), were assessed using the HBV-reporter cell line HepG2.2.15. RPT and ECR proved to efficiently inhibit HBV surface antigen (HBsAg) synthesis by 68.8 and 71.3%, respectively, and HBV pre-core antigen (HBeAg) production by 62.3 and 71.2%, respectively, after 5 days of treatment. Of note, RPT had a lower anti-HBV activity than ECR. In comparison, the reference drug lamivudine (LAM) inhibited HBsAg and HBeAg expression by 83.6 and 85.4%, respectively. Further molecular docking analysis revealed formations of strong complexes of RPT, ECR and LAM with HBV polymerase through interactions with binding pocket residues. Taken together, the present results demonstrated promising therapeutic potential of the novel -derived catechin and epicatechin for HBV, warranting their further molecular and pharmacological evaluation.